A carregar...
Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
Background: Administration of subcutaneous (SC) bortezomib in patients with multiple myeloma (MM) has increased in recent years. Yet, it is unclear whether there is sufficient evidence to support the use of SC bortezomib as a standard of care. Methods: A systematic review of 4 randomized controlled...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6529723/ https://ncbi.nlm.nih.gov/pubmed/31190749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S198117 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|